Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Mortality from cardiovascular disease in women with breast cancer - a nationwide registry study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiovascular disease in women with breast cancer - a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Martine Piccart
  • Marion Procter
  • Debora Fumagalli
  • Evandro de Azambuja
  • Emma Clark
  • Michael S Ewer
  • Eleonora Restuccia
  • Guy Jerusalem
  • Susan Dent
  • Linda Reaby
  • Hervé Bonnefoi
  • Ian Krop
  • Tsang-Wu Liu
  • Tadeusz Pieńkowski
  • Masakazu Toi
  • Nicholas Wilcken
  • Michael Andersson
  • Young-Hyuck Im
  • Ling Ming Tseng
  • Hans-Joachim Lueck
  • Marco Colleoni
  • Estefania Monturus
  • Mihaela Sicoe
  • Sébastien Guillaume
  • José Bines
  • Richard D Gelber
  • Giuseppe Viale
  • Christoph Thomssen
  • APHINITY Steering Committee and Investigators
Vis graf over relationer

PURPOSE: APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 to 1.00], P = .045) for patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), specifically those with node-positive or hormone receptor (HR)-negative disease. We now report the preplanned second interim overall survival (OS) and descriptive updated IDFS analysis with 74 months median follow-up.

METHODS: After surgery and central HER2-positive confirmation, 4,805 patients with node-positive or high-risk node-negative BC were randomly assigned (1:1) to either 1-year pertuzumab or placebo added to standard adjuvant chemotherapy and 1-year trastuzumab.

RESULTS: This interim OS analysis comparing pertuzumab versus placebo did not reach the P = .0012 level required for statistical significance (P = .17, hazard ratio 0.85). Six-year OS were 95% versus 94% with 125 deaths (5.2%) versus 147 (6.1%), respectively. IDFS analysis based on 508 events (intent-to-treat population) showed a hazard ratio of 0.76 (95% CI, 0.64 to 0.91) and 6-year IDFS of 91% and 88% for pertuzumab and placebo groups, respectively. The node-positive cohort continues to derive clear IDFS benefit from pertuzumab (hazard ratio 0.72 [95% CI, 0.59 to 0.87]), 6-year IDFS being 88% and 83%, respectively. Benefit was not seen in the node-negative cohort. In a subset analysis, IDFS benefit from pertuzumab showed a hazard ratio of 0.73 (95% CI, 0.59 to 0.92) for HR-positive disease and a hazard ratio of 0.83 (95% CI, 0.63 to 1.10) for HR-negative disease. Primary cardiac events remain < 1% in both the treatment groups. No new safety signals were seen.

CONCLUSION: This analysis confirms the IDFS benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early BC. Longer follow-up is needed to fully assess OS benefit.

TidsskriftJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Udgave nummer13
Sider (fra-til)1448-1457
Antal sider10
StatusUdgivet - 1 maj 2021

ID: 64496011